Amylin的山茱萸笔延迟了

每周一次GLP-1激动剂的笔设备的开发伯多森（埃塞纳西亚少数一周）袭击了障碍。Amylin (the drug’s manufacturer) had previously said that the pen would be available by late 2012 or early 2013. In a setback, however, the FDA has requested additional testing data, which is expected to delay the submission and approval of the pen until later next year. As a reminder, GLP-1 agonists are injectable type 2 diabetes drugs that stimulate the body to produce insulin and reduce glucose production only when blood glucose levels are too high. Because of these effects, GLP-1 agonists help improve blood glucose control without increasing the risk for hypoglycemia. GLP-1 agonists also suppress appetite, which can help people lose weight. Besides Bydureon, other currently available GLP-1 agonists include维多拉（Novo Nordisk的Liraglutide）和拜塔（淀粉蛋白的exenatide）。虽然这些其他药物需要比百枣更频繁的镜头（每天与Victoza每天两次与Byetta每天两次，而且每周与Bydureon相比），它们都进入易于使用的笔设备。目前，Bydureon使用类似于Glucagon注射的系统，这需要六步准备和注射药物（点击这里对于视频演示）。预计亚历顿笔将简化其管理。虽然笔上的确切细节尚未释放，但注射可能需要三个步骤：1）扭转装置以结合药物的组件;2）摇笔混合药物的组件;3）注射药物。-BK.